100 related articles for article (PubMed ID: 22569300)
1. [Circulating tumor cells and advanced prostate cancer].
Murez T; Droupy S; Rebillard X; Alix-Panabieres C
Bull Cancer; 2012 Jul; 99 Suppl 1():S4-15. PubMed ID: 22569300
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
[TBL] [Abstract][Full Text] [Related]
3. Molecular phenotyping of circulating tumour cells in patients with prostate cancer: prediction of distant metastases.
Giesing M; Driesel G; Molitor D; Suchy B
BJU Int; 2012 Dec; 110(11 Pt C):E1202-11. PubMed ID: 23046102
[TBL] [Abstract][Full Text] [Related]
4. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.
Gonzales JC; Fink LM; Goodman OB; Symanowski JT; Vogelzang NJ; Ward DC
Clin Genitourin Cancer; 2011 Sep; 9(1):39-45. PubMed ID: 21723797
[TBL] [Abstract][Full Text] [Related]
5. [Molecular staging of prostatic cancer].
Ravery V
Prog Urol; 1997 Dec; 7(6):925-9. PubMed ID: 9490136
[TBL] [Abstract][Full Text] [Related]
6. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
Gomella LG; Raj GV; Moreno JG
J Urol; 1997 Aug; 158(2):326-37. PubMed ID: 9224297
[TBL] [Abstract][Full Text] [Related]
7. Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer.
Okegawa T; Nutahara K; Higashihara E
Int J Urol; 2010 May; 17(5):466-75. PubMed ID: 20337729
[TBL] [Abstract][Full Text] [Related]
8. Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases.
Thiounn N; Saporta F; Flam TA; Pages F; Zerbib M; Vieillefond A; Martin E; Debré B; Chevillard S
Urology; 1997 Aug; 50(2):245-50. PubMed ID: 9255296
[TBL] [Abstract][Full Text] [Related]
9. Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer.
Paris PL; Kobayashi Y; Zhao Q; Zeng W; Sridharan S; Fan T; Adler HL; Yera ER; Zarrabi MH; Zucker S; Simko J; Chen WT; Rosenberg J
Cancer Lett; 2009 May; 277(2):164-73. PubMed ID: 19162393
[TBL] [Abstract][Full Text] [Related]
10. Molecular detection of micrometastases and circulating tumor cells in melanoma prostatic and breast carcinomas.
Ghossein RA; Carusone L; Bhattacharya S
In Vivo; 2000; 14(1):237-50. PubMed ID: 10757082
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
12. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.
Danila DC; Heller G; Gignac GA; Gonzalez-Espinoza R; Anand A; Tanaka E; Lilja H; Schwartz L; Larson S; Fleisher M; Scher HI
Clin Cancer Res; 2007 Dec; 13(23):7053-8. PubMed ID: 18056182
[TBL] [Abstract][Full Text] [Related]
14. Identification of circulating prostate cancer cells: a challenge to the clinical implementation of molecular biology (review).
Schamhart DH; Maiazza R; Kurth KH
Int J Oncol; 2005 Mar; 26(3):565-77. PubMed ID: 15703810
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer.
O'Flaherty JD; Gray S; Richard D; Fennell D; O'Leary JJ; Blackhall FH; O'Byrne KJ
Lung Cancer; 2012 Apr; 76(1):19-25. PubMed ID: 22209049
[TBL] [Abstract][Full Text] [Related]
16. Screening and identification of differentially expressed transcripts in circulating cells of prostate cancer patients using suppression subtractive hybridization.
Li X; Wong C; Mysel R; Slobodov G; Metwalli A; Kruska J; Manatt CS; Culkin DJ; Kropp BP; Lin HK
Mol Cancer; 2005 Aug; 4(1):30. PubMed ID: 16086835
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2009 Mar; 181(3):1091-7. PubMed ID: 19150091
[TBL] [Abstract][Full Text] [Related]
18. Landmarks in prostate cancer diagnosis: the biomarkers.
Artibani W
BJU Int; 2012 Oct; 110 Suppl 1():8-13. PubMed ID: 23046035
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
[TBL] [Abstract][Full Text] [Related]
20. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes.
Sher YP; Shih JY; Yang PC; Roffler SR; Chu YW; Wu CW; Yu CL; Peck K
Clin Cancer Res; 2005 Jan; 11(1):173-9. PubMed ID: 15671543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
